Cara R. Fiore, PhD
United States Food and Drug Administration
Senior Regulatory Scientist, Product Jurisdiction Administrator
Silver Spring, MD
Dr Fiore has been a Senior Regulatory Reviewer and Microbiologist in vaccines and live biotherapeutic products (LBPs) at the United States Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) since 2007. She has extensive regulatory and scientific experience in human vaccines and LBPs. In July 2024, Dr Fiore was promoted to Product Jurisdiction General Health Administrator in the Center Director’s Office in CBER where she continues to focus on regulation of vaccines, LBPs, and other products regulated by CBER. Dr Fiore is active in several agency-, federal government-, and worldwide working groups regarding regulation of CBER products and frequently interfaces with external stakeholders on behalf of CBER. Prior to joining the FDA, Dr Fiore was a Senior Scientist at the Office of Biomedical Advanced Research and Development Authority (BARDA) in the Department of Health and Human Service (DHHS). She was a Senior Scientist in Fermentation and Purification Vaccine Development at Nabi Biopharmaceuticals. Dr Fiore received her PhD from the School of Medicine, University of Maryland Baltimore in vaccine development. She received a BS Biology and a BA Anthropology from Tulane University prior to entering graduate school.
(Updated July 18, 2024)
Vance G. Fowler, MD
Duke University
Florence McAlister Distinguished Professor of Medicine
Durham, NC
Dr Fowler is the Florence McAlister Distinguished Professor of Medicine at Duke University Medical Center in the Departments of Medicine and Molecular Genetics & Microbiology. He has over 2 decades of continuous support as a principle investigator (PI) from the National Institutes of Health for clinical and translational research in Staphylococcus aureus and other antibiotic resistant bacterial infections. Dr Fowler created the S. aureus Bacteremia Group, cofounded the International Collaboration on Endocarditis, and has been the Contact PI of the Antibacterial Resistance Leadership Group since its inception in 2013. He has over 350 peer-reviewed publications with more than 33,000 citations.
(Updated July 18, 2024)